Commentary: Ligelizumab for chronic spontaneous urticaria.

Commentary: Ligelizumab for chronic spontaneous urticaria.
Br J Dermatol. 2020 Jan 30;:
Authors: Sabroe RA
Abstract
Chronic spontaneous urticaria (CSU) is a very disabling condition. It can be difficult to treat. Less than 50% of people respond to licenced dosages of H1-antihistamines (though up-dosing where safe increases the response rate). Additionally, only a small proportion respond to the addition of the leukotriene receptor antagonist (LTRA) montelukast.1,2.
PMID: 32002982 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - January 29, 2020 Category: Dermatology Authors: Sabroe RA Tags: Br J Dermatol Source Type: research